Tracking a patient with no technetium-99m-pyrophosphate myocardial uptake at surgical valve replacement for aortic stenosis
Koji Takahashi1
Daisuke Sasaki2
Takaaki Iwamura2
Shuhei Yamamoto2
Mitsuharu Ueda3
Nobuhisa Yamamura4
Mako Yoshino5
Daijiro Enomoto5
Hiroe Morioka5
Shigeki Uemura5
Takafumi Okura5
Tomoki Sakaue1
Katsuji Inoue1
1.Department of Community Emergency Medicine,Ehime University Graduate School of Medicine,Ehime,Japan;Department of Cardiology,Yawatahama City General Hospital,Ehime,Japan2.Department of Radiology,Yawata-hama City General Hospital,Ehime,Japan3.Department of Neurology,Graduate School of Medical Sciences,Kum-amoto University,Kumamoto,Japan4.Department of Clinical Pathology,Yawatahama City General Hospital,Ehime,Japan5.Department of Cardiology,Yawatahama City General Hospital,Ehime,Japan
摘要：Aortic stenosis(AS)is the most common valv-ular heart disease,with a prevalence of over 4％among octogenarians.[1]The prevalence of autopsy-confirmed wild-type transthyretin cardiac amyloidosis(ATTRwt-CA)increases with age,account-ing for 25％of patients aged 85 years and older in Europe and 12％of patients older than 80 years in Japan.
机标关键词：patientwithaorticmyocardialpyrophosphatereplacementstenosissurgical
论文发表日期：2025-09-30
在线出版日期：2025-11-14（本平台首次上网日期，不代表文献的发表时间）
页数：6( 828-833 )